BioNTech SE

BNTXintermediary

BioNTech is a German biotechnology company that co-developed the first authorized mRNA COVID-19 vaccine with Pfizer. It is now leveraging its mRNA platform for individualized cancer vaccines, infectious disease programs, and cell therapies.

⇄ Compare

产品与营收

产品营收占比

营收构成 ($4.8B)

静态数据（加载实时财务…）

COVID-19 Vaccine Revenue (68%)

Collaboration Revenue (Pfizer) (18%)

R&D Grants & Other (14%)

业务板块构成与主要客户

产品详情

Comirnaty (COVID-19 Vaccine)55%

mRNA-based COVID-19 vaccine developed with Pfizer

Oncology mRNA (BNT111, BNT122)15%

Individualized mRNA cancer vaccines targeting solid tumors

Infectious Disease Pipeline10%

mRNA vaccines for influenza, shingles, and malaria

供应链关系

合作伙伴

Pfizer Inc.

Comirnaty COVID vaccine co-development

影响: Critical — Pfizer is primary commercialization partner

竞争对手

Moderna, Inc.

mRNA vaccines and oncology

影响: Primary mRNA competitor

Regeneron Pharmaceuticals

Cancer immunotherapy

影响: Competing in oncology

宏观与市场背景

제약 / 바이오行业新闻

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

近期催化剂

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

AI 分析

点击「获取 AI 分析」以获得 BioNTech SE 的 AI 供应链分析。

企业信息

总部

Mainz, Germany

成立时间

2008

员工人数

6,000+

官网

biontech.com

行业概况 — 제약 / 바이오

行业新闻